



美迪西生物医药



# Integrated Preclinical Drug Discovery and Development Services

## **FOCUS IND Filing**

SHANGHAI MEDICILON INC.

# COMPANY PROFILE

From its inception in 2004, Shanghai Medicilon Inc. (STAR Market, stock code: 688202.SH) has been committed to providing comprehensive research and development (R&D) services to biopharmaceutical companies, research institutions, and any organizations working in the preclinical space, with the primary objective of supporting and accelerating pharmaceutical, biopharmaceutical and medical device R&D worldwide.



## A Comprehensive CRO for Pre-Clinical Pharmaceutical R&D

- End-to-end services and solutions covering the entire spectrum of preclinical biopharmaceutical R&D. Supporting everything from target discovery, candidate development, preclinical screening and safety through IND submission
- Focus on communication and collaboration with clients in a variety of target indication areas such as neoplasms, neurological diseases, diabetes, inflammation, etc

## State-of-the-Art Facilities

- Three R&D centers with over 794,000 ft<sup>2</sup> of lab space in Shanghai, China
- AAALAC accredited animal facilities
- GLP/GMP compliant facilities, instrumentation with FDA and NMPA regulations

## High-Performance Teams


- Internationally trained scientists with Ph.D. degree and/or with 10+ years of R&D and management experience
- Timely support and consultations through one-on-one communication

## IP Protection

- Strict internal policies and excellent historical track record



## SERVICE SCOPE



Address: 1 Broadway, 9th Fl, Cambridge Innovation Center  
Cambridge, MA 02142

Email: [marketing@medicilon.com](mailto:marketing@medicilon.com)

Website: [www.medicilon.com](http://www.medicilon.com)




# IND APPROVAL

Medicilon provides the IND application for the preclinical services. Medicilon is the CRO that fulfill both the China and US GLP standards. Medicilon could submit the application for both FDA and NMPA for your new drug. Since 2004, we have successfully helped our clients to submit their new drug application to FDA and NMPA and met the requirements of the FDA and NMPA. We have undergone several inspections and passed all of them. Medicilon will provide an efficient, cost-effective and professional service to help our clients to achieve their goals.





## Medicinal Development Service Timelines for Small Molecules



Medicilon assists global clients with the IND and ANDA applications to the FDA and NMPA

- Submission of IND/ANDA applications to FDA and NMPA on behalf of the clients
- Assist with IND registration package preparation in the format of SEND and eCTD
- Project management
- Compile, assess, and review technical documents for IND and ANDA submissions
- Multilevel of reviewing process to ensure the accuracy and compliance before filing
- A dedicated, experienced project manager maintains frequent communications with the FDA/NMPA agency throughout the application progress till the final approval is granted



Address: 1 Broadway, 9th Fl, Cambridge Innovation Center  
Cambridge, MA 02142

Email: [marketing@medicilon.com](mailto:marketing@medicilon.com)

Website: [www.medicilon.com](http://www.medicilon.com)



## SHANGHAI MEDICILON INC.

---

Address: 585 Chuanda Road, Shanghai 201299, China Tel: +86 (21) 5859-1500

Email: [marketing@medicilon.com](mailto:marketing@medicilon.com)

Website: [www.medicilon.com](http://www.medicilon.com)

### Service Hotline

400-780-8018 (China) | +86 (21) 5028-2001 (global)